Table 2 Clinical trials targeting FAP in metastatic cancers
From: Metastasis-associated fibroblasts: an emerging target for metastatic cancer
Study | Phase | Type of cancer | MAFs-related drug | Status | Outcome |
|---|---|---|---|---|---|
NCT04826003 | I/II | Metastatic Colorectal Cancer | RO7122290 | Ongoing | Not applicable. |
2017-003961-83 | I | Advanced solid tumors | RO7122290 | Ongoing | Objective response rate was 18.4 % when RO7122290 was used in combination with atezolizumab. |
NCT00004042 | I | Advanced or metastatic colorectal cancer | sibrotuzumab (F19) | Complete | Not reported. |
Hofheinz 2003 | II | Metastatic Colorectal Cancer | sibrotuzumab (F19) | Complete | Failed. Progressive disease was observed in all patients except for 2 patients with stable disease. |
NCT03386721 | II | Advanced/metastatic head and neck, oesophageal and cervical cancers | Simlukafusp Alfa (RO6874281) | Ongoing | Not applicable. |
NCT02627274 | I | metastatic head and neck cancer and breast cancer | Simlukafusp Alfa (RO6874281) | Ongoing | Preliminary data showed that objective responses over 6 months were observed in 3 patients. |
NCT02558140 | I | Locally advanced or metastatic solid tumors | RO6874813 | Complete | Safety profile was favorable and preliminary antitumor activity was observed in 1 patient. |